References
- Haverkamp LJ, Appel V, Appel SH. Natural history of amyo- trophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707–719.
- Nightingale SL. From the Food and Drug Administration. Riluzole available for ALS under treatment IND. JAMA 1995; 274: 292.
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585–591.
- Wokke J. Riluzole. Lancet 1996; 348: 795–799.
- Braakman R. Management of cervical spondylotic myelopathy and radiculopathy. J Neurol Neurosurg Psychiatry 1994; 57: 257–263.
- Van den Berg LH, Franssen H, Wokke JH. Improvement of multifocal motor neuropathy during long-term weekly treatment with human immunoglobulin. Neurology 1995; 45: 987–988.
- Swash M, Leigh N. Criteria for diagnosis of familial amyo- trophic lateral sclerosis: European FALS Collaborative Group. Neuromuscul Disord 1992; 2: 7–9.
- Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP on behalf of the Scottish Motor Neuron Disease Research Group. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1996; 60: 147–151.
- Van den Berg LH, Franssen H, Wokke JH. The long-term effect of intravenous immunoglobulin treatment in multi- focal motor neuropathy. Brain 1998; 121: 421–428.